Thus, it is likely that the PCSK9-i could impact on circulating apoB-rich lipoproteins not only quantitatively but also qualitatively improving the overall lipid profile, and possibly explaining the lower CLC observed in our cohort of FH subjects. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.